Mark Gudesblatt
South Shore Neurologic Associates,
77 Medford Avenue, Patchogue, NY 11772
Tanzania
Research Article
Outcomes of a Switch to Fingolimod to Treat Relapsing Multiple Sclerosis: A Patient Subgroup Post Hoc Analysis
Author(s): Mark Gudesblatt, Neetu Agashivala, Simrat Randhawa, Stan Li, Luigi Barbato and Barry SingerMark Gudesblatt, Neetu Agashivala, Simrat Randhawa, Stan Li, Luigi Barbato and Barry Singer
Objective: The EPOC study assessed the effects of switching from an injectable disease-modifying therapy (glatiramer acetate or one of three interferon beta drugs) to once-daily, oral fingolimod 0.5 mg in patients with relapsing MS. Outcomes were assessed in several patient subgroups at 6 months between patients who switched to fingolimod and those who continued on iDMT.
Methods: Differences in study endpoints between those who switched to fingolimod and those who continued on an iDMT were evaluated by age, gender, baseline Expanded Disability Status Scale score, MS duration, number of relapses in the previous year, previous treatment, previous treatment duration, and reason for switching. The primary endpoint was the change from baseline to month 6 in the Treatment Satisfaction Questionnaire for Medication Global Satisfaction score. Seconda.. Read More»
